Orbimed Advisors Llc Purchases 597,729 Shares of Traws Pharma (NASDAQ:TRAW) Stock

Traws Pharma, Inc. (NASDAQ:TRAW) major shareholder Orbimed Advisors Llc bought 597,729 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were acquired at an average price of $1.67 per share, with a total value of $998,207.43. Following the purchase, the insider owned 1,203,250 shares in the company, valued at $2,009,427.50. This trade represents a 98.71% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Traws Pharma Stock Up 7.4%

Shares of NASDAQ:TRAW opened at $1.30 on Thursday. The business has a 50 day moving average price of $1.65 and a 200 day moving average price of $1.93. Traws Pharma, Inc. has a twelve month low of $0.97 and a twelve month high of $3.27. The company has a market cap of $13.20 million, a price-to-earnings ratio of 1.40 and a beta of 1.61.

Traws Pharma (NASDAQ:TRAW) last announced its earnings results on Wednesday, April 15th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.51. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.06 million. Analysts anticipate that Traws Pharma, Inc. will post -2.62 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH upgraded Traws Pharma to a “strong-buy” rating in a research note on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.00.

Hedge Funds Weigh In On Traws Pharma

Several large investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP acquired a new position in Traws Pharma in the 4th quarter valued at approximately $56,000. XTX Topco Ltd raised its holdings in Traws Pharma by 294.2% in the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after acquiring an additional 31,502 shares in the last quarter. Ikarian Capital LLC raised its holdings in Traws Pharma by 2,280.0% in the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock valued at $766,000 after acquiring an additional 649,649 shares in the last quarter. Squadron Capital Management LLC acquired a new position in Traws Pharma in the 4th quarter valued at approximately $806,000. Finally, Boothbay Fund Management LLC acquired a new position in Traws Pharma in the 4th quarter valued at approximately $220,000. Institutional investors and hedge funds own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.